11,460 Bottles of Chlorthalidone Recalled Across the United States: What Every Patient Needs to Know

The Recall That Every Hypertension Patient in America Should Check

If you take a prescription blood pressure medication in a small white tablet — particularly one dispensed in a white plastic pharmacy bottle with an April 2027 expiration date — this article is for you. The FDA has announced a nationwide recall of 11,460 bottles of chlorthalidone tablets, USP, 25 mg, following the discovery of a manufacturing defect that may render the medication ineffective for the patients taking it.

The recall was initiated voluntarily on June 5, 2026 by Inventia Healthcare Limited, a pharmaceutical manufacturer based in Mumbai, India, after testing revealed that certain lots of its 25 mg chlorthalidone tablets had failed dissolution specifications. On June 22, 2026, the FDA formally classified the recall as Class II — its category for situations where use of the recalled product may cause temporary or medically reversible adverse health effects, or where the probability of serious harm is remote but present. The bottles were distributed across the United States by Rising Pharma Holdings, Inc., of New Jersey.

The specific numbers: 11,460 bottles total, split between 100-count bottles carrying batch code RISA24001 and 1,000-count bottles carrying batch code RISB24002. The expiration date on every affected bottle is April 2027 — which means that without this recall, some of these bottles could have remained in pharmacy stock or patients' medicine cabinets for nearly another year.

What Failed Dissolution Specifications Actually Means for Your Health

The phrase "failed dissolution specifications" is pharmaceutical regulatory language that translates directly into a specific health risk that every affected patient needs to understand.

Dissolution testing is the process by which pharmaceutical manufacturers evaluate how effectively a tablet or capsule dissolves and releases its active ingredients once it enters the body's digestive system. When a tablet is swallowed, it passes through the stomach and into the gastrointestinal tract, where it is expected to break down and release its medication within a defined window of time at a defined rate. The drug's therapeutic effect depends entirely on this dissolution process — a tablet that does not dissolve correctly cannot release its active ingredient into the bloodstream at the rate and concentration necessary to produce the intended medical outcome.

When dissolution testing reveals that a batch of tablets has failed its dissolution specifications, it means the tablets in that batch are dissolving more slowly, less completely, or at a different rate than the drug's approved formula requires. The tablets may still contain the correct amount of chlorthalidone — the problem is not contamination or incorrect dosage on the label. The problem is that when you swallow the tablet, your body may not be able to absorb the medication as intended, because the tablet is not breaking down as it should.

For a patient taking chlorthalidone to control blood pressure, a tablet that fails to dissolve correctly could mean receiving less than the full therapeutic dose even though they are taking their medication as prescribed. Their blood pressure, which chlorthalidone is supposed to control, may remain elevated without them or their doctor knowing why. A patient who believes they are being treated is, in effect, being undertreated — and undertreated hypertension carries real cardiovascular risk including increased probability of stroke, heart attack, and kidney damage over time.

This is the specific hazard that gives the Class II classification its significance. The product is not immediately dangerous in the way a contaminated drug might be. But it is potentially ineffective in ways that create serious downstream health risk for patients who depend on it.

What Chlorthalidone Is and Who Takes It

Chlorthalidone is a thiazide-like diuretic — a class of medication that works by acting on the kidneys to increase the production and excretion of urine, thereby reducing the volume of fluid in the bloodstream and the pressure that fluid exerts on blood vessel walls. The mechanism is well established and has been used in hypertension treatment since the 1960s. Chlorthalidone specifically has earned a strong evidence base as one of the more effective diuretics for blood pressure management, and it is recommended in multiple major clinical guidelines including those from the American College of Cardiology and the American Heart Association.

Its uses, according to the Mayo Clinic, include treating hypertension either alone or in combination with other blood pressure medications, treating fluid retention associated with congestive heart failure, treating fluid retention from severe liver disease, kidney disease, or treatment with hormones or steroids, and other conditions where reducing fluid volume is therapeutically beneficial.

Hypertension — high blood pressure — affects approximately one in three American adults. It is largely asymptomatic, meaning many patients have no direct symptoms that tell them their blood pressure is elevated. They rely entirely on their medication to keep the condition controlled. For these patients, an ineffective medication is particularly dangerous because the treatment failure is silent: nothing feels wrong, the patient continues taking their pills faithfully, and the elevated blood pressure is doing its invisible damage to arteries, the heart, and kidneys without any signal that the medication is not working.

The Specific Batch Information: Is Your Bottle Affected?

The recall covers two specific batch codes that should be printed on the label of every affected bottle. Patients who take 25 mg chlorthalidone tablets dispensed in 100-count bottles should check for batch code RISA24001. Patients dispensed the medication in 1,000-count bottles — which are more typically held by pharmacies for dispensing rather than given directly to patients, though not exclusively — should check for batch code RISB24002.

Every affected bottle has an expiration date of April 2027. The NDC — National Drug Code — numbers on affected bottles should also be checked against the FDA's official recall notice, available at fda.gov/safety/recalls-market-withdrawals-safety-alerts.

The tablets were manufactured by Inventia Healthcare Limited in Mumbai and distributed in the United States by Rising Pharma Holdings, headquartered in New Jersey. Pharmacies that received stock from Rising Pharma during the relevant period are among the dispensing points from which affected tablets may have reached patients.

What to Do If You Have an Affected Bottle

The FDA's guidance is clear, and it aligns with the approach recommended for any Class II prescription drug recall. Patients who believe they may have affected bottles should not simply stop taking the medication without medical consultation. Abruptly stopping blood pressure medication — particularly if the patient's hypertension is not otherwise well controlled — carries its own risk of rebound elevation and cardiovascular events.

Contact your prescribing physician or pharmacist as soon as possible and explain the recall situation. Bring your bottle or a photo of the label so the batch code can be verified. Your healthcare provider will confirm whether your specific bottle is part of the recall and will advise on next steps — which may include switching to a different batch of chlorthalidone from a different manufacturer, switching to an alternative blood pressure medication in the same or a related class, or having your blood pressure monitored more closely while the medication is replaced.

Retail pharmacies that dispensed affected bottles should be proactively contacting patients who received the recalled medication, and many will be doing so. If you have not heard from your pharmacy and you believe you may have an affected bottle, do not wait for their call — reach out to them directly.

Rising Pharma Holdings, as the distributor, is responsible for coordinating the physical return of recalled product from pharmacies. Individual patients who have partially or fully used affected bottles should follow the FDA's medication disposal guidelines if they still have unused tablets: do not flush prescription medications unless the label or a pharmacist's guidance specifically says to do so. Mix tablets with an undesirable substance such as used coffee grounds, seal in a container, and dispose in household trash, or use an authorised drug take-back location.

The Broader Recall Context: Not an Isolated Event

This chlorthalidone recall joins a pattern of blood pressure medication recalls that has been visible across the past several years of FDA enforcement activity. The most consequential blood pressure medication recall category in recent years has been the NDMA contamination saga — N-nitrosodimethylamine, a probable human carcinogen that was found in multiple batches of valsartan, losartan, irbesartan, and other medications in the angiotensin II receptor blocker class, leading to recalls affecting tens of millions of patients across multiple years.

The October recall cited by NBC Chicago — involving more than half a million bottles of Prazosin Hydrochloride recalled over concerns about unsafe levels of a cancer-causing chemical — represents the contamination end of the recall spectrum, where the risk to patients is a carcinogen rather than a dissolution failure.

The chlorthalidone recall is different in character: this is not contamination but a manufacturing quality failure that affects the drug's effectiveness rather than introducing a harmful substance. The risk profile is therefore different — dissolution failure does not expose patients to a toxic chemical, but it does leave their hypertension undertreated in ways that can be equally harmful over time.

The FDA's Class II classification reflects this distinction. Class I recalls — the highest severity — cover situations where the product has a reasonable probability of causing serious adverse health consequences or death. Class II covers situations where the product may cause temporary or medically reversible adverse health consequences, with a remote probability of serious harm. Class III covers situations where the product is unlikely to cause adverse health consequences. Dissolution failure in a blood pressure diuretic sits at Class II because the harm — undertreated hypertension leading to cardiovascular events — is medically serious but dependent on cumulative exposure and individual patient circumstances rather than immediate acute toxicity.

What Patients Should Watch For

In the days and weeks after this recall becomes widely known, patients who have been taking affected bottles may begin to notice signs consistent with undertreated hypertension. These include headaches, particularly in the morning or at the back of the head, dizziness or lightheadedness, vision changes, shortness of breath, chest pain or discomfort, irregular heartbeat, and swelling in the legs or ankles — symptoms that may indicate elevated blood pressure or fluid retention that the medication has not been adequately controlling.

These symptoms should not be dismissed or attributed to other causes without checking blood pressure. Any patient on blood pressure medication who experiences new or worsening symptoms of this kind should have their blood pressure checked promptly — either at a pharmacy, at their doctor's office, or using a home blood pressure monitor — and report the result to their healthcare provider.

Blood pressure control is one of the most important modifiable risk factors for cardiovascular disease, stroke, and kidney disease. For the millions of Americans managing hypertension with prescription medication, the effectiveness of that medication is not an abstract pharmaceutical quality concern. It is a daily life-or-death variable. The chlorthalidone recall is a reminder that the quality of the medication reaching patients depends on manufacturing processes that operate globally, under supply chains that extend from Mumbai laboratories to New Jersey distributors to pharmacy shelves in every American state — and that when those processes fail, the consequences are borne by the patients who trusted that what was in the bottle would do what the label said.

Sources

1. TODAY — "Thousands of Bottles of Popular Blood Pressure Medication Chlorthalidone Recalled" (June 23, 2026)
   https://www.today.com/health/recall/chlorthalidone-recall-blood-pressure-medication-class-ii-rcna351375
2. Fox Business — "Thousands of bottles of blood pressure medication recalled nationwide" (June 22, 2026)
   https://www.foxbusiness.com/lifestyle/thousands-bottles-blood-pressure-medication-recalled-nationwide
3. NewsNation — "Blood pressure medication recalled nationwide over failed dissolution practices: FDA" (June 22, 2026)
   https://www.newsnationnow.com/us-news/recalls/blood-pressure-medication-recalled-nationwide-fda/
4. NBC Chicago — "Thousands of bottles of blood pressure medication recalled in U.S." (June 22, 2026)
   https://www.nbcchicago.com/news/local/thousands-of-bottles-of-blood-pressure-medication-recalled-nationwide/3951934/
5. WAFB (Gray News) — "Blood pressure medication recalled for potential ineffectiveness" (June 22, 2026)
   https://www.wafb.com/2026/06/22/blood-pressure-medication-recalled-potential-ineffectiveness/
6. U.S. Food and Drug Administration — Official Recall Notice: Chlorthalidone Tablets USP, 25 mg (Inventia Healthcare Limited, June 5, 2026)
   https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts
7. Cleveland Clinic — "Chlorthalidone" (drug information reference)
   https://my.clevelandclinic.org/health/drugs/19518-chlorthalidone-tablets
8. Mayo Clinic — "Chlorthalidone (Oral Route)" (drug information reference)
   https://www.mayoclinic.org/drugs-supplements/chlorthalidone-oral-route/description/drg-20061745